A study presented at the American College of Cardiology conference and published in the New England Journal of Medicine showed that Novo Nordisk’s Wegovy improved symptoms and physical function in patients with obesity, diabetes, and heart failure with preserved ejection fraction (HFpEF). This is the second trial conducted by Novo on Wegovy in HFpEF, following positive results from a previous trial in patients with obesity and HFpEF without diabetes. Novo has submitted the results to regulators in hopes of getting approval for a new indication in HFpEF. Wegovy recently received FDA clearance for preventing cardiovascular complications in people with heart disease.
Source link
Positive trial results set up Wegovy for heart failure application
